Jump to content

Search the Community

Showing results for tags 'liquid biopsy'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • WELCOME NEW MEMBERS!
    • INTRODUCE YOURSELF!
  • STORIES OF SURVIVORSHIP
    • SHARE YOUR LUNG CANCER STORY
  • DISCUSSION FORUMS
    • GENERAL
    • LC SURVIVORS
    • NSCLC GROUP
    • SCLC GROUP
    • US VETERANS
    • CAREGIVER RESOURCE CENTER
  • TREATMENT FORUMS
    • CHEMOTHERAPY
    • IMMUNOTHERAPY
    • RADIATION
    • SURGERY
    • SUPPORTIVE CARE
  • LUNG CANCER NAVIGATOR
    • LUNG CANCER NAVIGATOR
  • NEWS / ADVOCACY
    • LUNG CANCER IN THE NEWS
    • ADVOCACY
  • LIVING WELL
    • HEALTHY LIVING / RECIPES
    • HOPE
    • JUST FOR FUN
  • SUPPORT
    • SUPPORT RESOURCES
  • GRIEF
    • GRIEF
  • TERMS OF USE
    • FEATURES AND SUPPORT

Blogs

  • An Advocates Perspective
  • Cheryncp123's Blog
  • Stay The Course
  • Lung Cancer Stories
  • Spree
  • Volunteer Voices
  • Caregivers Connection
  • Stage IV Treatment With S.B.R.T.
  • Susan Cornett
  • Robin S
  • Lung Cancer & Health Insurance: Tips on managing the mayhem.
  • Daze of My Life by Ken Lourie
  • CommUNITY Connection
  • Heather Smith
  • Lisa Haines
  • Veteran's Oprions
  • Cancer: holding his hand until his last breath
  • A Healthy Place
  • Lenny Blue
  • The Roscopal Effect
  • Ro
  • Sharron P
  • Loi ich suc khoe cua qua chi tu
  • Shanesga
  • Facts are stubborn things, but statistics are pliable

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


First name


Last name


City


Province or district (if non-US)


Postal code


Country


Interests

Found 5 results

  1. LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, announced today the recipients of its 2018 Career Development Awards (CDA) for lung cancer research. These coveted awards fund critical lung cancer research projects and offer the recipients world-class mentorship by LUNGevity’s prestigious Scientific Advisory Board. “We are excited to support these exceptionally talented new investigators. Interestingly, all three of these projects involve liquid biopsy-based approaches to detecting and optimizing treatment of lung cancer. These new projects may define new avenues for applying liquid biopsies in the clinical setting,” notes Charles Rudin, MD, PhD, Professor and Chief, Thoracic Oncology Service, at Memorial Sloan Kettering Cancer Center and chair of LUNGevity’s Scientific Advisory Board. “We believe that this outstanding group of awardees will help make progress in improving outcomes for lung cancer patients.” LUNGevity is proud to support the following 2018 Career Development Award researchers: Kellie Smith, PhD, Johns Hopkins School of Medicine, Immunometabolic T cell profiling as a prognostic liquid biopsy in non-small cell lung cancer. Dr. Smith’s research group will work to develop a liquid biopsy that predicts advanced-stage non-small cell lung cancer patient responses to combination immunotherapy regimens. Jeffrey Thompson, MD, University of Pennsylvania, Development of markers to predict response to immunotherapy in NSCLC. Dr. Thompson’s laboratory is working to develop blood-based tests to identify individuals most likely to respond to immunotherapy with minimum side effects, helping to ensure customized immunotherapies for advanced-stage non-small cell lung cancer patients. Edwin Yau, MD, PhD, Roswell Park Cancer Institute, Lung cancer detection by CRISPR-based detection of circulating tumor DNA. Dr. Yau’s team is developing a quick and cost-effective blood test for early detection of lung cancer that will complement CT screening. “By funding young investigators, LUNGevity keeps outstanding scientists, still early in their careers, in the lung cancer space. We work closely with these researchers with the hope of seeing them become the next generation of scientific superstars,” says Andrea Ferris, President and CEO of LUNGevity. “The CDA program encourages their continued development in the field of lung cancer research to grow a strong pipeline of dedicated lung cancer researchers.” Under the stewardship of LUNGevity’s Scientific Advisory Board, a group of 21 prominent scientists and researchers, LUNGevity ensures that grants are awarded to those researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as for extending and improving lives of lung cancer survivors. LUNGevity is the only lung cancer organization with a programmatic focus on early detection and a robust Career Development Award Program. Our researchers are working on finding a better way to detect lung cancer, and to better diagnose, treat, and prevent its recurrence. The foundation’s overall research program, including CDA awards, is a crucial factor in moving the science forward to improve outcomes for people living with lung cancer. LUNGevity’s Scientific Research Program is supported by individual donors, the American Lung Association, Bristol-Myers Squibb, The Thomas G. Labrecque Foundation, Upstage Lung Cancer, and the Schmidt Legacy Foundation. Read the full press release.
  2. Here is the weekly clip report: U.S. News & World Report "From the 'Big C' to Cancer" https://health.usnews.com/health-care/patient-advice/articles/2018-03-21/from-the-big-c-to-cancer Healio “Lower-Limb Arterial Thrombosis May Be Marker of Cancer” https://www.healio.com/cardiac-vascular-intervention/peripheral/news/online/{f342b55f-87eb-4edc-a0eb-608633079467}/lower-limb-arterial-thrombosis-may-be-marker-of-cancer Medscape “How to Improve Diversification of Patients with Cancer in Clinical Trials” https://www.medscape.com/viewarticle/894210 Oncology Nursing News "New Treatments for Lesser-Known Targets in NSCLC Are Emerging" http://www.oncnursingnews.com/web-exclusives/new-treatments-for-lesserknown-targets-in-nsclc-are-emerging Smithsonian Magazine “Could Immunotherapy Lead the Way to Fighting Cancer?” https://www.smithsonianmag.com/innovation/immunotherapy-lead-way-fighting-cancer-180968392/ Medscape “From ALK to T790M: The Role of Liquid Biopsy in Lung Cancer” https://www.medscape.com/viewarticle/894215 Medical Xpress “RNA-Based Therapeutic Inhibits a Metabolic Pathway in Tumor-Initiating Lung Cancer Cells” https://medicalxpress.com/news/2018-03-rna-based-therapeutic-inhibits-metabolic-pathway.html Bloomberg “Robots Could Replace Surgeons in the Battle Against Cancer” https://www.bloomberg.com/news/features/2018-03-23/robots-could-replace-surgeons-in-the-battle-against-cancer
  3. Here is the weekly clip report: The ASCO Post “Stand Up To Cancer Launches ‘Cancer Interception’ Teams to Detect and Treat Cancer at Earliest Stages” http://www.ascopost.com/issues/november-25-2017/stand-up-to-cancer-launches-cancer-interception-teams-to-detect-and-treat-cancer-at-earliest-stages/ Stanford Medicine News Center “Stanford Scientists among Those Funded by Stand Up To Cancer” https://med.stanford.edu/news/all-news/2017/11/stanford-scientists-among-those-funded-by-stand-up-to-cancer.html Immuno-Oncology News “Imfinzi Increases Time for Non-Small Cell Lung Cancer to Progress, Phase 3 Trial Shows” https://immuno-oncologynews.com/2017/11/28/phase-3-trial-shows-imfinzi-lengthens-time-for-non-small-cell-lung-cancer-to-return/ Targeted Oncology “Ahead of NSCLC Approval Decision, FDA Now Weighing Durvalumab Data in NEJM” http://www.targetedonc.com/news/ahead-of-nsclc-approval-decision-fda-now-weighing-durvalumab-data-in-nejm OncLive “Immunotherapy to Have Emerging Role in Squamous Cell Lung Cancer” http://www.onclive.com/web-exclusives/immunotherapy-to-have-emerging-role-in-squamous-cell-lung-cancer Business Wire “Impassioned Lung Cancer Survivors Join Your Cancer Game Plan, Merck to Advocate for Others Facing This Highly Stigmatized Disease” http://www.businesswire.com/news/home/20171129005025/en/Impassioned-Lung-Cancer-Survivors-Join-Cancer-Game The Baltimore Sun “Life After Lung Cancer: How One Survivor is Fighting for Others” http://www.baltimoresun.com/bp/blt-ara-31849-life-after-lung-cancer-how-one-survivor-is-fighting-for-others-20171129-adstory.html National Press Club “Life After Cancer: Addressing Survivorship in Cancer Care” http://www.press.org/events/life-after-cancer-addressing-survivorship-cancer-care Markets Insider “Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept’s Liquid Biopsy Test in Immunotherapy” http://markets.businessinsider.com/news/stocks/Biocept-and-UC-San-Diego-Medical-Center-Announce-Clinical-Study-Collaboration-to-Demonstrate-Utility-of-Biocept-s-Liquid-Biopsy-Test-in-Immunotherapy-1009786790 Medical Xpress “Two-Drug Combination May Boost Immunotherapy Response in Lung Cancer Patients” https://medicalxpress.com/news/2017-11-two-drug-combination-boost-immunotherapy-responses.html Reuters “FDA Aims to Approve More Drugs Based on Early Clinical Data” https://www.reuters.com/article/us-fda-hearing-testimony/fda-aims-to-approve-more-drugs-based-on-early-clinical-data-idUSKBN1DU2DS Healio “Eight Important Updates in Lung Cancer” https://www.healio.com/hematology-oncology/lung-cancer/news/online/{56102e9b-63d2-4eea-8859-01b452dbe2b3}/eight-important-updates-in-lung-cancer Investor’s Business Daily “This Biotech Launched to a Record High on Cancer Test Approval” https://www.investors.com/news/technology/this-biotech-launched-to-a-record-high-on-cancer-test-approval/ DOD Congressionally Directed Medical Research Programs “Melissa Crouse – Lung Cancer Warrior, Mentor and Advocate” http://cdmrp.army.mil/cwg/stories/2017/melissa_crouse_profile Business Wire “FDA Approves Foundation Medicine’s FoundationOne Cdx, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics” http://www.businesswire.com/news/home/20171130006320/en/FDA-Approves-Foundation-Medicine’s-FoundationOne-CDx™-Comprehensive Markets Insider “Advocates Reveal Cancer Survivorship Challenges and Resources During National Comprehensive Cancer Network’s Patient Advocacy Summit” http://markets.businessinsider.com/news/stocks/Advocates-Reveal-Cancer-Survivorship-Challenges-and-Resources-during-National-Comprehensive-Cancer-Network-s-Patient-Advocacy-Summit-1010204005
  4. August 15, 2017 https://www.healio.com/hematology-oncology/lung-cancer/news/in-the-journals/{2febb384-604e-4805-8094-f89e7e2646e7}/liquid-biopsy-offers-option-for-egfr-testing-without-lung-tumor-tissue Blood assays identified EGFR mutations in patients with advanced non-small cell lung cancer with insufficient tumor biopsies, according to a prospective analysis published in Annals of Oncology. “The clinical benefits of tyrosine kinase inhibitors in stage IIIB to IV NSCLC patients carrying sensitizing mutations in the EGFR gene are well established, and EGFR testing in tumor tissue has become a routine clinical practice,” Miguel Angel Molina-Vila, BSc, PhD, laboratory director of Pangaea Oncology at Quirón Dexeus University Hospital in Barcelona, and colleagues wrote. “However, 5% to 20% of advanced NSCLC patients cannot be biopsied or the tumor tissue in biopsies or cytological samples is insufficient for successful genetic analysis.” Studies have explored whether circulating-free DNA from serum or plasma of patients with advanced NSCLC can be used to reliably determine EGFRmutations. However, there have been no studies of patients treated with TKIs based only on a positive EGFR result in blood. Molina-Vila and colleagues analyzed EGFR mutations in the circulating-free DNA of 1,138 patients with stage IIIB to stage IV NSCLC using a real-time polymerase chain reaction assay. Because no commercial kits were available at the time testing commenced, researchers developed and validated a PNA-Q-PCR assay for the detection of mutations in exons 19, 20 (p.T790M) Search and 21 (p.L858R and p.L861Q). “The assay is simple, not more expensive than tissue analysis, has a short turnaround time and its limits of detection, sensitivity (75.9%) and specificity (100%) are in the range of other reported methodologies,” the researchers wrote. “The main limitation of the assay is that it cannot detect the relatively infrequent mutations in exon 18 of EGFR.” The goal of the study included to determine if this method may be used as a surrogate to select patients with no biopsy or insufficient tumor tissue for treatment with EGFR TKI therapy. In total, 1,033 patients underwent prospective testing at disease presentation, of whom 1,026 were evaluable (men, 55.8%; former smokers, 46.8%). Of them, 113 (11%; women, 66.4%; never smokers, 63.7%) has a sensitizing mutation in circulating-free DNA, including 75 with exon 19 deletions and 38 with exon 21 point mutations. Thirty-one patients were positive only in plasma and 11 in only in serum. The researchers measured concentration of DNA using Qubit (Thermo Fisher Scientific) to evaluate the blood samples of a subset of patients with EGFRmutations (n = 40) and wild-type EGFR (n = 40). More than 60% of circulating-free DNA samples contained less than 10 pg mutant genomes/l. Researchers then determined mutation load in 149 serum and plasma samples from 91 patients with EGFR mutations. More than 50% of samples contained less than 10 mutated genomes/µl with allelic fractions below 0.25%. Median mutation load appeared higher in plasma than serum samples (0.23% vs. 0.12%), and in samples positive for exon 19 compared with exon 21 deletions (0.26% vs. 0.07%). In addition, 105 patients who progressed following EGFR TKI therapy also underwent prospective screening. The assay detected sensitizing mutations in 56.2% of these patients and the p.T790M resistance mutation in 35.2%. The researchers retrospectively collected clinical information from 18 patients treated with TKIs based exclusively on the results of the EGFR testing in blood. Thirteen patients achieved a partial response for an overall response rate of 72%. Median PFS was 11 months. Duration of response ranged from 5 months to 18 months in eight patients who had available data. Two patients who harbored a p.L858R mutation progressed after 5 and 8 months, whereas the duration of response range from 7 months to not reached in the six patients who harbored exon 19 mutations. “Some of the patients identified as EGFR positive, based solely on the results of the PNA-Q-PCR assay, showed remarkable responses to targeted therapy,” Molina-Vila and colleagues wrote. Although blood assays proved to be a feasible alternative to tumor biopsies, the researchers noted this method will not become the standard of care. “’Liquid’ biopsies will never replace tumor biopsies, which constitute unique sources of information that cannot be obtained by any other means,” they wrote. “However, our results demonstrate that prospective EGFR analysis in blood can be used to select patients for TKI therapy when no tumor tissue is available for genetic testing.” – by Kristie L. Kahl Disclosure: Molina-Vila reports he has no relevant financial disclosures. Please see the full study for a list of all other researchers’ relevant financial disclosures.
  5. Having enough tissue available for biomarker (aka mutation, genetic, or molecular) testing can also be an important consideration. Before a biopsy is done, the patient should speak with his or her oncologist about having the tumor sample profiled. To find out if targeted cancer therapy makes sense for an individual with lung cancer, that person’s tumor tissue will be tested. The goal is to determine whether or not an appropriate target is present. The following video describes diagnostic testing for mutations in lung cancer.
×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.